English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Open

Background  Clinical diagnosis of Alzheimer disease (AD) is only 70% accurate. Reduced cerebral blood flow (CBF) and metabolism in parieto‐temporal and posterior cingulate cortex may assist diagnosis. While widely accepted that   18 F‐fluoro‐2‐deoxyglucose positron emission tomography (  18 F‐FDG PET) has superior accuracy to CBF‐SPECT for AD, there are very limited head‐to‐head data from clinically relevant populations and these studies relied on clinical diagnosis as the reference standard.    Aims  To compare directly the accuracy of CBF‐SPECT and  18 F‐FDG PET in patients referred for diagnostic studies in detecting β‐amyloid PET confirmed AD.    Methods  A total of 126 patients, 56% with mild cognitive impairment and 44% with dementia, completed both CBF‐SPECT and  18 F‐FDG PET as part of their diagnostic assessment, and subsequently underwent β‐amyloid PET for research purposes. Transaxial slices and Neurostat 3D‐SSP analyses of  18 F‐FDG PET and CBF‐SPECT scans were independently reviewed by five nuclear medicine clinicians blinded to all other data. Operators selected the most likely diagnosis and their diagnostic confidence. Accuracy analysis used final diagnosis incorporating β‐amyloid PET as the reference standard.    Results  Clinicians reported high diagnostic confidence in 83% of  18 F‐FDG PET compared to 67% for CBF‐SPECT ( P  = 0.001). All reviewers showed individually higher accuracy using  18 F‐FDG PET. Based on majority read, the combined area under the receiver operating characteristic curve in diagnosing AD was 0.71 for  18 F‐FDG PET and 0.61 for CBF‐SPECT ( P  = 0.02). The sensitivity of  18 F‐FDG PET and CBF‐SPECT was 76% versus 43% ( P  < 0.001), while specificity was 74% versus 83% ( P  = 0.45).    Conclusions   18 F‐FDG PET is superior to CBF‐SPECT in detecting AD among patients referred for the assessment of cognitive impairment.

internal medicine journal

Head‐to‐head comparison of cerebral blood flow  single‐photon emission computed tomography  and   18 F‐fluoro‐2‐deoxyglucose positron emission tomography  in the diagnosis of Alzheimer disease